Mainz Biomed NV has launched the eAArly DETECT 2 feasibility study, aimed at validating previous results on advanced adenomas using a large population of approximately 2,000 average risk patients.
Mainz Biomed N.V., a molecular genetics diagnostic company, announced significant achievements in the first quarter of 2025 and provided an update on its progress toward FDA premarket approval. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results